Could a common arthritis drug protect the hearts of women with endometriosis?

NCT ID NCT05069740

Recruiting now Disease control Sponsor: Penn State University Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether salsalate, an anti-inflammatory drug, can reduce the elevated risk of cardiovascular disease seen in women with endometriosis. Researchers will measure blood vessel function and markers of inflammation in 24 women with endometriosis compared to healthy controls. The goal is to understand whether targeting inflammation can improve heart health in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an anti-inflammatory drug called salsalate
What this could lead to: If it works, this could point toward a way to lower heart disease risk in women with endometriosis.
What could go wrong: This is a very early, small trial (24 people) testing a mechanism, not a proven treatment. Salsalate may not improve heart function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS

Contacts and locations

Locations

The Pennsylvania State University
RECRUITING

University Park, Pennsylvania, 16801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.